pharmaserve (north west) development company limited
pharmaserve (north west) development company limited Company Information
Company Number
09863420
Next Accounts
Sep 2025
Shareholders
obg scientific division ltd
Group Structure
View All
Industry
Other research and experimental development on natural sciences and engineering
Registered Address
ayrton saunders house, parliament business park, liverpool, L8 7BA
Website
pharmaservenorthwest.co.ukpharmaserve (north west) development company limited Estimated Valuation
Pomanda estimates the enterprise value of PHARMASERVE (NORTH WEST) DEVELOPMENT COMPANY LIMITED at £354.1k based on a Turnover of £315.7k and 1.12x industry multiple (adjusted for size and gross margin).
pharmaserve (north west) development company limited Estimated Valuation
Pomanda estimates the enterprise value of PHARMASERVE (NORTH WEST) DEVELOPMENT COMPANY LIMITED at £312.8k based on an EBITDA of £58.9k and a 5.31x industry multiple (adjusted for size and gross margin).
pharmaserve (north west) development company limited Estimated Valuation
Pomanda estimates the enterprise value of PHARMASERVE (NORTH WEST) DEVELOPMENT COMPANY LIMITED at £263.9k based on Net Assets of £137k and 1.93x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Pharmaserve (north West) Development Company Limited Overview
Pharmaserve (north West) Development Company Limited is a live company located in liverpool, L8 7BA with a Companies House number of 09863420. It operates in the other research and experimental development on natural sciences and engineering sector, SIC Code 72190. Founded in November 2015, it's largest shareholder is obg scientific division ltd with a 100% stake. Pharmaserve (north West) Development Company Limited is a established, micro sized company, Pomanda has estimated its turnover at £315.7k with high growth in recent years.
Upgrade for unlimited company reports & a free credit check
Pharmaserve (north West) Development Company Limited Health Check
Pomanda's financial health check has awarded Pharmaserve (North West) Development Company Limited a 1.5 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 6 areas for improvement. Company Health Check FAQs
2 Strong
2 Regular
6 Weak
Size
annual sales of £315.7k, make it smaller than the average company (£4.4m)
- Pharmaserve (north West) Development Company Limited
£4.4m - Industry AVG
Growth
3 year (CAGR) sales growth of 26%, show it is growing at a faster rate (6.7%)
- Pharmaserve (north West) Development Company Limited
6.7% - Industry AVG
Production
with a gross margin of 47.1%, this company has a comparable cost of product (47.1%)
- Pharmaserve (north West) Development Company Limited
47.1% - Industry AVG
Profitability
an operating margin of -71.8% make it less profitable than the average company (3.6%)
- Pharmaserve (north West) Development Company Limited
3.6% - Industry AVG
Employees
with 3 employees, this is below the industry average (46)
- Pharmaserve (north West) Development Company Limited
46 - Industry AVG
Pay Structure
on an average salary of £64.5k, the company has an equivalent pay structure (£64.5k)
- Pharmaserve (north West) Development Company Limited
£64.5k - Industry AVG
Efficiency
resulting in sales per employee of £105.2k, this is less efficient (£124k)
- Pharmaserve (north West) Development Company Limited
£124k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- Pharmaserve (north West) Development Company Limited
- - Industry AVG
Creditor Days
its suppliers are paid after 159 days, this is slower than average (44 days)
- Pharmaserve (north West) Development Company Limited
44 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Pharmaserve (north West) Development Company Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 0 weeks, this is less cash available to meet short term requirements (31 weeks)
0 weeks - Pharmaserve (north West) Development Company Limited
31 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 94%, this is a higher level of debt than the average (44.4%)
94% - Pharmaserve (north West) Development Company Limited
44.4% - Industry AVG
PHARMASERVE (NORTH WEST) DEVELOPMENT COMPANY LIMITED financials
Pharmaserve (North West) Development Company Limited's latest turnover from December 2023 is estimated at £315.7 thousand and the company has net assets of £137 thousand. According to their latest financial statements, we estimate that Pharmaserve (North West) Development Company Limited has 3 employees and maintains cash reserves of £154 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | |
|---|---|---|---|---|---|---|---|---|
| Turnover | ||||||||
| Other Income Or Grants | ||||||||
| Cost Of Sales | ||||||||
| Gross Profit | ||||||||
| Admin Expenses | ||||||||
| Operating Profit | ||||||||
| Interest Payable | ||||||||
| Interest Receivable | ||||||||
| Pre-Tax Profit | ||||||||
| Tax | ||||||||
| Profit After Tax | ||||||||
| Dividends Paid | ||||||||
| Retained Profit | ||||||||
| Employee Costs | ||||||||
| Number Of Employees | ||||||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | |
|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 90,748 | 205,919 | ||||||
| Intangible Assets | 2,178,773 | 2,430,975 | 2,687,958 | 2,898,353 | 2,893,357 | 1,421,645 | ||
| Investments & Other | 585 | |||||||
| Debtors (Due After 1 year) | ||||||||
| Total Fixed Assets | 2,178,773 | 2,430,975 | 2,687,958 | 2,898,353 | 2,984,105 | 1,628,149 | ||
| Stock & work in progress | ||||||||
| Trade Debtors | ||||||||
| Group Debtors | 1,166,460 | 1,068,396 | 617,549 | 1 | ||||
| Misc Debtors | 85,672 | 2,178 | 14,863 | 244,014 | ||||
| Cash | 154 | 244 | 3,070 | 1,434 | 485,296 | 853 | ||
| misc current assets | ||||||||
| total current assets | 85,826 | 2,422 | 1,169,530 | 1,084,693 | 1,346,859 | 854 | 1 | |
| total assets | 2,264,599 | 2,433,397 | 3,857,488 | 3,983,046 | 4,330,964 | 1,629,003 | 1 | |
| Bank overdraft | ||||||||
| Bank loan | ||||||||
| Trade Creditors | 73,009 | 39,454 | 38,381 | 30,559 | 3,000 | 688 | ||
| Group/Directors Accounts | 1,374,040 | 1,440,397 | 2,481,511 | 2,772,942 | 3,099,844 | 1,655,259 | ||
| other short term finances | ||||||||
| hp & lease commitments | ||||||||
| other current liabilities | 127,273 | 3,605 | 76,058 | 16,160 | 162,926 | 41,760 | ||
| total current liabilities | 1,574,322 | 1,483,456 | 2,595,950 | 2,819,661 | 3,265,770 | 1,697,707 | ||
| loans | ||||||||
| hp & lease commitments | ||||||||
| Accruals and Deferred Income | ||||||||
| other liabilities | ||||||||
| provisions | 553,276 | 586,212 | 586,212 | 445,521 | 385,130 | |||
| total long term liabilities | 553,276 | 586,212 | 586,212 | 445,521 | 385,130 | |||
| total liabilities | 2,127,598 | 2,069,668 | 3,182,162 | 3,265,182 | 3,650,900 | 1,697,707 | ||
| net assets | 137,001 | 363,729 | 675,326 | 717,864 | 680,064 | -68,704 | 1 | |
| total shareholders funds | 137,001 | 363,729 | 675,326 | 717,864 | 680,064 | -68,704 | 1 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Operating Profit | ||||||||
| Depreciation | 10,518 | 5,162 | ||||||
| Amortisation | 285,666 | 285,672 | 168,806 | |||||
| Tax | ||||||||
| Stock | ||||||||
| Debtors | 83,494 | -1,164,282 | 83,201 | 221,696 | 861,562 | 1 | ||
| Creditors | 33,555 | 1,073 | 7,822 | 27,559 | 2,312 | 688 | ||
| Accruals and Deferred Income | 123,668 | -72,453 | 59,898 | -146,766 | 121,166 | 41,760 | ||
| Deferred Taxes & Provisions | -32,936 | 140,691 | 60,391 | 385,130 | ||||
| Cash flow from operations | ||||||||
| Investing Activities | ||||||||
| capital expenditure | ||||||||
| Change in Investments | -585 | 585 | ||||||
| cash flow from investments | ||||||||
| Financing Activities | ||||||||
| Bank loans | ||||||||
| Group/Directors Accounts | -66,357 | -1,041,114 | -291,431 | -326,902 | 1,444,585 | 1,655,259 | ||
| Other Short Term Loans | ||||||||
| Long term loans | ||||||||
| Hire Purchase and Lease Commitments | ||||||||
| other long term liabilities | ||||||||
| share issue | ||||||||
| interest | ||||||||
| cash flow from financing | ||||||||
| cash and cash equivalents | ||||||||
| cash | -90 | -2,826 | 1,636 | -483,862 | 484,443 | 853 | ||
| overdraft | ||||||||
| change in cash | -90 | -2,826 | 1,636 | -483,862 | 484,443 | 853 |
pharmaserve (north west) development company limited Credit Report and Business Information
Pharmaserve (north West) Development Company Limited Competitor Analysis
Perform a competitor analysis for pharmaserve (north west) development company limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other micro companies, companies in L 8 area or any other competitors across 12 key performance metrics.
pharmaserve (north west) development company limited Ownership
PHARMASERVE (NORTH WEST) DEVELOPMENT COMPANY LIMITED group structure
Pharmaserve (North West) Development Company Limited has no subsidiary companies.
Ultimate parent company
2 parents
PHARMASERVE (NORTH WEST) DEVELOPMENT COMPANY LIMITED
09863420
pharmaserve (north west) development company limited directors
Pharmaserve (North West) Development Company Limited currently has 6 directors. The longest serving directors include Mr Padraic O'Brien (Nov 2015) and Mr Philip Didlick (Nov 2015).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Padraic O'Brien | England | 45 years | Nov 2015 | - | Director |
| Mr Philip Didlick | United Kingdom | 48 years | Nov 2015 | - | Director |
| Mr Gerald O'Brien | United Kingdom | 76 years | Nov 2015 | - | Director |
| Mr Gerald O'Brien | England | 76 years | Nov 2015 | - | Director |
| Mr Padraic O'Brien | United Kingdom | 45 years | Nov 2015 | - | Director |
| Mr Mark Bromiley | 45 years | Jul 2021 | - | Director |
P&L
December 2023turnover
315.7k
+84%
operating profit
-226.7k
0%
gross margin
47.2%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
137k
-0.62%
total assets
2.3m
-0.07%
cash
154
-0.37%
net assets
Total assets minus all liabilities
pharmaserve (north west) development company limited company details
company number
09863420
Type
Private limited with Share Capital
industry
72190 - Other research and experimental development on natural sciences and engineering
incorporation date
November 2015
age
10
incorporated
UK
ultimate parent company
accounts
Small Company
last accounts submitted
December 2023
previous names
N/A
accountant
DSG AUDIT
auditor
-
address
ayrton saunders house, parliament business park, liverpool, L8 7BA
Bank
-
Legal Advisor
-
pharmaserve (north west) development company limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 2 charges/mortgages relating to pharmaserve (north west) development company limited. Currently there are 0 open charges and 2 have been satisfied in the past.
pharmaserve (north west) development company limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for PHARMASERVE (NORTH WEST) DEVELOPMENT COMPANY LIMITED. This can take several minutes, an email will notify you when this has completed.
pharmaserve (north west) development company limited Companies House Filings - See Documents
| date | description | view/download |
|---|
